These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18401224)

  • 1. The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan.
    Saito I; Kushiro T; Hirata K; Sato Y; Kobayashi F; Sagawa K; Hiramatsu K; Komiya M
    J Clin Hypertens (Greenwich); 2008 Apr; 10(4):272-9. PubMed ID: 18401224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
    Heagerty AM; Mallion JM
    Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertension.
    Mallion JM; Heagerty A; Laeis P
    J Hypertens; 2007 Oct; 25(10):2168-77. PubMed ID: 17885562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
    Malacco E; Omboni S; Mallion JM; Volpe M;
    High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.
    Fogari R; Taddei S; Holm-Bentzen M; Baszak J; Melani L; Schumacher K
    Clin Drug Investig; 2010; 30(9):581-97. PubMed ID: 20593911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
    Ewald S; vor dem Esche J; Uen S; Neikes F; Vetter H; Mengden T
    Clin Drug Investig; 2006; 26(8):439-46. PubMed ID: 17163276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
    Saito I; Kushiro T; Zenimura N; Matsushita Y; Sagawa K; Hiramatsu K; Yamaguchi F
    J Nephrol; 2012; 25(5):699-708. PubMed ID: 22020401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of olmesartan medoxomil in Chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements.
    Wang JG; Sun NL; Ke YN; Zhang BH; Ikegami N; Zhu JR
    Clin Drug Investig; 2012 Nov; 32(11):729-34. PubMed ID: 23018282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension.
    Germino FW; Neutel JM; Dubiel R; Maa JF; Chavanu KJ
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):325-33. PubMed ID: 22920048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.
    Barrios V; Brommer P; Haag U; Calderón A; Escobar C
    Clin Drug Investig; 2009; 29(7):427-439. PubMed ID: 19499960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Olmesartan medoxomil: a review of its use in the management of hypertension.
    Scott LJ; McCormack PL
    Drugs; 2008; 68(9):1239-72. PubMed ID: 18547134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.
    Volpe M; Brommer P; Haag U; Miele C
    Clin Drug Investig; 2009; 29(1):11-25. PubMed ID: 19067471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study.
    Ogihara T; Saruta T; Shimada K; Kuramoto K
    Hypertens Res; 2009 Dec; 32(12):1148-54. PubMed ID: 19816505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early antihypertensive efficacy of olmesartan medoxomil.
    Saito I; Kushiro T; Ishikawa M; Matsushita Y; Sagawa K; Hiramatsu K; Komiya M
    J Clin Hypertens (Greenwich); 2008 Dec; 10(12):930-5. PubMed ID: 19120719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study.
    Barrios V; Escobar C; Calderon A; Böhm M
    Vasc Health Risk Manag; 2009; 5():723-9. PubMed ID: 19756164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
    Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
    Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
    Omboni S; Malacco E; Mallion JM; Volpe M
    Drugs Aging; 2012 Dec; 29(12):981-92. PubMed ID: 23179896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.